The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer

SpringerPlus

Table 3 The correlations between overall survival and various clinicopathological factors

	Univariate analysis			Multivariate analysis
	Hazard ratio	95 % CI	p value	Hazard ratio	95 % CI	p value
Gender (female vs. male)	1.473	0.895–2.423	0.128
Age (≥65 vs. <65)	1.492	0.907–2.454	0.115
Location of primary tumor (colon vs. rectum)	1.273	0.769–2.108	0.348
Detection of unresectable tumor (synchronous vs. metachronous)	1.595	0.946–2.688	0.080	1.099	0.595–2.030	0.763
Histological type (poorly, mucinous vs. well, moderately)	1.417	0.688–2.916	0.344
Peritoneal dissemination (yes vs. no)	1.124	0.609–2.075	0.708
The number of organs affected by metastasis (≥2 vs. <2)	1.775	1.078–2.923	0.024	1.115	0.622–1.997	0.715
Pretreatment CEA (>5 ng/ml vs. ≤5 ng/ml)	2.193	0.940–5.113	0.069	1.370	0.526–3.571	0.520
Molecular targeted therapy (yes vs. no)	0.391	0.227–0.676	0.001	0.341	0.186–0.626	0.001
Pretreatment CRP/ALB ratio (>0.183 vs. ≤0.183)	2.301	1.390–3.807	0.001	1.866	1.057–3.295	0.031
Pretreatment NLR (>3 vs. ≤3)	3.777	2.191–6.511	<0.001	2.706	1.483–4.939	0.001

CEA carcinoembryonic antigen, CRP/ALB ratio C-reactive protein to albumin ratio, NLR neutrophil to lymphocyte ratio